Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Shares Outstanding (Weighted Average) (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $357345.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 23.27% to $357345.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $357345.0, a 23.27% increase, with the full-year FY2025 number at $357345.0, up 23.27% from a year prior.
  • Shares Outstanding (Weighted Average) was $357345.0 for Q4 2025 at Iovance Biotherapeutics, down from $364037.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $213.7 million in Q1 2023 to a low of $224481.0 in Q2 2023.
  • A 3-year average of $18.1 million and a median of $296573.0 in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Biggest YoY gain for Shares Outstanding (Weighted Average) was 26.88% in 2024; the steepest drop was 99.88% in 2024.
  • Iovance Biotherapeutics' Shares Outstanding (Weighted Average) stood at $235131.0 in 2023, then rose by 23.28% to $289877.0 in 2024, then rose by 23.27% to $357345.0 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Shares Outstanding (Weighted Average) are $357345.0 (Q4 2025), $364037.0 (Q3 2025), and $328721.0 (Q2 2025).